Phase 3Completed
Immunogenicity and Safety of Gardasil-9 and Cervarix
Immunogenicity and Safety of Gardasil-9 and Cervarix When Administered to 9-10-year-old Subjects According to 0-6 Month Schedule
- Sponsor
- Laval University (Academic or other)
- Enrollment
- 376 enrolled
- Conditions
- HPV Vaccines Immunogenicity and Safety
- Interventions
- Immunogenicity two doses of Gardasil-9; Immunogenicity Cervarix and Gardasil-9
- Ages
- children
- Registry
- NCT02567955
Full record on ClinicalTrials.gov
From the registry
A ninevalent HPV vaccine (Gardasil-9) has been recently approved for clinical use. No data on immunogenicity and safety of interchangeable use of the ninevalent and the bivalent vaccine (Cervarix) are available. The main objective of this study is to assess the immunogenicity of ninevalent and bivalent HPV vaccines when administered to 9-10-year-old girls and boys according to 0-6 month schedule.
Primary outcomes
- Comparison of proportion of subjects with detectable antibodies to 9 HPV genotypes included in the Gardasil-9 vaccine observed in two study arms
History
Last registry update
Study completion
Primary completion
Registered
Started